Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

Trial Profile

Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Solid tumours
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Acronyms INSPIRE
  • Most Recent Events

    • 12 Sep 2017 Results (n=23) of analysis validating the previously developed RAD classifier from recurrent/metastatic squamous cell carcinoma of the head and neck patients, with patients from INSPIRE. presented at the 42nd European Society for Medical Oncology Congress
    • 06 Jun 2017 Interim results (n=18) assessing immunological and genomic characterisation presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Technical feasibility data (n=53, as of 16 Jan 2017), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top